Agilent Technologies Completes Acquisition of BioSystem Development Business

01-03-2012: Agilent Technologies Inc. announced it has completed the acquisition of the BioSystem Development business. BioSystem Development is a privately held company that develops and manufactures the AssayMAP Microchromatography platform to meet the analytical needs of the life sciences industry. Financial details of the transaction were not disclosed.

As life science discovery and development continues to move toward a better understanding of biological responses to disease, and has an increased emphasis on protein-based therapeutics by pharmaceutical companies, the need for automated, quality protein sample preparation and analysis has become critical.

BioSystem Development’s AssayMAP platform, based on disposable microchromatography cartridges, enables for the first time, automation of complex, multi-step sample preparation workflows. These include protein purification, characterization and analysis solutions for bioprocess development, biomarker identification and analysis, as well as a variety of other life science research applications.

The acquisition formalizes and streamlines the ongoing collaboration between BioSystem Development and Agilent to combine AssayMAP technology with Agilent's industry-leading automated liquid handling platforms, to reduce discovery and development time and increase lab efficiency.

Contact / Request information

Request further information free of charge:

Watchlist

This is where you can add this news to your personal favourites

View the original article here

Agilent Technologies Publishes Industry’s First Compendium to Test for Synthetic Marijuana Compounds

05-27-2011: Agilent Technologies Inc. announced availability of the industry’s first GC/MS compendium to test for synthetic cannabinoids, recently declared controlled substances by the U.S. Drug Enforcement Agency. They are most commonly found in “herbal incense” blends.

The compendium, available from Agilent at no cost to qualified forensics labs, contains detailed procedures for sample preparation and GC/MS method, plus a searchable mass-spectral library to test for 35 synthetic cannabinoids and their derivatives. The method and library were developed in collaboration with the Criminalistics Division of NMS Labs, an independent forensic laboratory certified by the American Board of Forensic Toxicology and the American Society of Crime Laboratory Directors.

“These compounds had not been controlled until November of 2010, when health concerns prompted the DEA to evoke an emergency ban,” said Tom Gluodenis, Ph.D., Agilent forensic and toxicology business manager. “They present a number of analytical challenges. Formulations are rapidly evolving. When one is banned, it can quickly be replaced by a new one. They’re often sold in botanical matrixes as ‘herbal incense’ and other products, which presents additional challenges. We published this compendium to help labs get a handle on this dynamic situation.”

The DEA currently controls six versions of synthetic cannabinoids: JWH-018, JWH-073, JWH-200, CP-47-497 (C7), CP-47-497 (C8) and HU-210. There are more than 20 uncontrolled forms, and this number is expected to grow.

Here you can receive further information concerning the news opposite directly from the publisher:

This is where you can add this news to your personal favourites

View the original article here